Results 111 to 120 of about 153,171 (297)

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

Cancer in kidney transplantation

, 2008
Cancer in the transplanted kidney is rare, and its clinical and surgical management can be controversial. We report 3 cases of cancer in renal transplantation (1 case of renal cell carcinoma and 2 cases of transitional cell carcinoma) and their treatment.
BETTINI E, Cosciani Cunico S., Bettini, E., ZANI, Danilo, MORONI A, Simeone C., SIMEONE, Claudio, ANTONELLI A, Antonelli, A., Antonelli A., Moroni A., Moroni, A., Zani, D., COSCIANI CUNICO, Sergio, Simeone, C., Zani D., Bettini E., Cosciani Cunico, S.   +17 more
core   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Managing Juvenile Myelomonocytic Leukemia in Resource-Constraint Setting: New Hope with Isotretinoin-based Cytoreductive Therapy

Haematology Journal of Bangladesh
Juvenile myelomonocytic leukaemia (JMML) is a highly aggressive myeloid neoplasm of early childhood. Currently the only curative treatment for this potentially fatal disease is haematopoietic stem cell transplantation (HSCT), but cure rate is only 50 ...
Eshita Reza Khan, Ferdousi Begum, Sabina Karim   +2 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm in a young female: Rare and challenging

, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic malignancy with an aggressive behavior, seen commonly in the elderly age group and usually involves the skin.
Ketan Modak, Vivek S Radhakrishnan, Deepak Kumar Mishra, Jeevan Kumar Garg   +3 more
core   +1 more source

Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti‐Inflammatory Response Syndromes by Targeting PF4+ Macrophages in Acute Pancreatitis

Advanced Science, EarlyView.
ABSTRACT Acute pancreatitis (AP) begins with pancreatic local inflammation, leading to the onset of systemic inflammatory response syndrome (SIRS), followed by compensatory anti‐inflammatory response syndrome (CARS), which causes immune paralysis and higher mortality rate.
Liwei Liu, Guanqun Li, Dongxu Lu, Haoran Ding, Tianqi Lu, Yuhang Sui, Can Zhang, Yu Xie, Rui Kong, Hua Chen, Xuewei Bai, Hongtao Tan, Dongbo Xue, Xianzhi Meng, Le Li, Bei Sun   +15 more
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Leukemia Successfully Treated by Autologous Hematopoietic Stem Cell Transplantation to a Remission of 48-Month Duration

Case Reports in Hematology, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare subtype of AML characterized by the clonal proliferation of precursors of plasmacytoid dendritic cells. It presents with an aggressive behavior.
Deniz Goren Sahin, Olga Meltem Akay, Hava Üsküdar Teke, Neslihan Andıc, Eren Gunduz, Zafer Gulbas   +5 more
doaj   +1 more source

Post-transplant Lymphoproliferative Disease Presenting as a Mass in the Left Ventricle in a Heart Transplant Recipient at Long-term Follow-up

, 2009
Neoplasms are among the most common solid-organ transplant complications, occurring in 11.7% of all transplant recipients and in 6% to 15% of heart transplant recipients, according to early studies.
Gaia, Diego Felipe [UNIFESP], Branco, João Nelson Rodrigues [UNIFESP], Fonseca, José Honório de Almeida Palma da [UNIFESP], Buffolo, Enio [UNIFESP], Teles, Andre [UNIFESP], Guilhen, José Cícero Stocco [UNIFESP], Teles, Carlos Alberto [UNIFESP]   +6 more
core   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report

, 2016
Blastic plasmocytoid dendritic cell neoplasm is characterized by aggressive behavior with a tendency for systemic dissemination and a predilection for skin, lymph nodes, soft tissues, peripheral blood, or bone marrow.
Martinez-Serra, Jordi, Daumal-Domenech, Jaume, Gutierrez, Antonio, Garcia Recio, Marta, Ramos-Asensio, Rafael, Sampol Mayol, Antonia, Bento, Leyre, Gines, Jordi   +7 more
core   +1 more source